Kyowa Hakko Kirin

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) revealed positive interim data from the second-stage study of KRN23 for tumor-induced osteomalacia (TIO) treatment. The company indicated its interim data at 24 weeks from the first eight patients showed KRN23 improved serum phosphorus levels and bone...